Home / 2020 / October / 02

Daily Archives: October 2, 2020

Constellation Brands Elects Nicholas Fink of Fortune Brands Home & Security, Inc. to Its Board of Directors

Constellation Brands, Inc.

Nicholas I. Fink, CEO, Fortune Home Brands & Security, Inc.

VICTOR, N.Y., Oct. 02, 2020 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today the election of Nicholas I. Fink, chief executive officer of Fortune Brands Home & Security, Inc., to serve as a member of its board of directors, effective as of the close of business on January 4, 2021. This election increases the size of Constellation’s board from 12 to 13 members.

“We are excited to welcome Nick to our board of directors,” said Rob Sands, Constellation Brands’ Executive Chair of the Board of Directors. “Nick brings extensive beverage alcohol, international business, and legal experience, and has a proven track record of leveraging consumer insights to meet consumer needs in fast moving, highly regulated markets. Nick will serve as a tremendous asset for our board as we work to continue building industry-leading brands people love and remain focused on our proven strategy of long-term, profitable, and sustainable growth.”

In January 2020, Fink was appointed as chief executive officer of Fortune Brands Home & Security, Inc., a Fortune 500 global home and security products manufacturer of trusted, well-known brands such as MasterBrand Cabinets, Moen, Master Lock, SentrySafe, and more. Previously, Fink served as president and chief operating officer for the company and focused on identifying opportunities to maximize the company’s growth potential. Before joining Fortune Brands in 2015, Fink held several roles with increasing levels of responsibility at present-day Beam Suntory, Inc., including president, Asia Pacific and South America, and chief strategy officer.

“I’m thrilled to join the board of directors at Constellation Brands, one of the fastest-growing CPG companies over the last several years,” said Fink. “I’ve long admired Constellation from my time in the industry and remain impressed by the company’s ability to stay at the forefront of consumer trends. I look forward to working with the rest of the board and lending my perspective to help sustain the company’s success well into the future.”

Fink earned his bachelor’s degree from the Institut d’Etudes Des Relations Internationales in Paris, France, and a law degree from Northwestern University.

At Constellation Brands (NYSE: STZ and STZ.B), our mission is to build brands that people love because we believe sharing a toast, unwinding after a day, celebrating milestones, and helping people connect, are Worth Reaching For. It’s worth our dedication, hard work, and the bold calculated risks we take to deliver more for our consumers, trade partners, shareholders, and communities in which we live and work. It’s what has made us one of the fastest-growing large CPG companies in the U.S. at retail, and it drives our pursuit to deliver what’s next.

Today, we are a leading international producer and marketer of beer, wine, and spirits with operations in the U.S., Mexico, New Zealand, and Italy. Every day, people reach for our high-end, iconic imported beer brands such as Corona Extra, Corona Light, Corona Premier, Modelo Especial, Modelo Negra, and Pacifico, and our high-quality premium wine and spirits brands, including the Robert Mondavi Brand Family, Kim Crawford, Meiomi, The Prisoner Brand Family, SVEDKA Vodka, Casa Noble Tequila, and High West Whiskey.

But we won’t stop here. Our visionary leadership team and passionate employees from barrel room to boardroom are reaching for the next level, to explore the boundaries of the beverage alcohol industry and beyond. Join us in discovering what’s Worth Reaching For.

To learn more, follow us on Twitter @cbrands and visit www.cbrands.com.

Mike McGrew 773-251-4934 / michael.mcgrew@cbrands.com
Amy Martin 585-678-7141 / amy.martin@cbrands.com
Patty Yahn-Urlaub 585-678-7483 / patty.yahn-urlaub@cbrands.com
Bob Czudak 585-678-7170 / bob.czudak@cbrands.com

A PDF containing multimedia is available at: http://ml.globenewswire.com/Resource/Download/0bae2e5e-b217-4b21-a8d4-bcc984dab17e

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/00fbb02b-62c6-4346-893b-f126b4384089

Attempts to smuggle ciggies into Singapore foiled

Singapore authorities seized 7,559 cartons of duty-unpaid cigarettes from two Malaysia-registered lorries at the Tuas Checkpoint on Sept 28.

In a statement here, the republic’s Immigration & Checkpoints Authority (ICA) said three male Malaysians aged 22, 25 and 41 years old, have been handed over to Singapore Customs for further investigations.

The ICA said the first case was detected at around 4.00am when its officers noticed anomalies in the scanned images of the lorry.

Upon further checks, 5,059 cartons of duty-unpaid cigarettes were found hidden in a consignment of tissue rolls.

About 10 minutes later, another lorry was directed by ICA officers for further checks and 2,500 cartons of duty-unpaid cigarettes were found hidden in boxes containing pineapples.

The total duty and Goods and Services Tax (GST) evaded amounted to about $656,299 and $52,981 respectively, it said.

Source: BERNAMA News Agency

Relay Medical and Fio Corporation Announces High-Volume Manufacturing Partner for its COVID-19 Mobile Testing Device, Fionet, to Support Scaled-Up Production

Fionet Devices

Fionet Mobile Devices

  • Relay & Fio announces engagement with contact manufacturer KeyTronic for high-volume production of its COVID-19 mobile testing device, which enables rapid COVID-19 testing & tracking in community-based settings
  • KeyTronic is a world class, US-based and FDA-approved medical device contract manufacturer, recently selected as a Top 10 Contract Manufacturing Service Provider for 20201
  • Recently announced delivery of COVID-19 software in Kenya has been deployed to first 10 clinics in Meru County
  • Signed new agreement for a research pilot with a large, European multinational medtech network
  • Fionet has been submitted to Health Canada for expedited access to address community-based testing and tracking. FRR is simultaneously working towards Fionet regulatory approval in the US and EU.

TORONTO, Oct. 02, 2020 (GLOBE NEWSWIRE) — Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), and Fio Corporation (“Fio”), together Fionet Rapid Response Group (“FRR”), announce that its Fionet pandemic response devices will be produced by US-based, FDA-approved, high-volume contract manufacturer, KeyTronic, which is now creating a Fionet device assembly line. KeyTronic (NASDAQ: KTCC) offers turnkey services and global reach and is already producing other COVID-related medical devices.

FRR has approximately 1000 devices being prepared for manufacture, with initial runs of the assembly line expected in October. The company has paid for the manufacturing line set ups and 50% of the cost of the first batch of 165 units and will pay the balance upon completion within 6 to 8 weeks.

“In August, we focused on implementing our vision for adapting Fionet to COVID. In September, we focused on bringing this vision to the market, which resulted in agreements for initial deployment we are signing. We now moved to engage a high-quality, high-volume manufacturer to fulfill orders,” said Dr Michael Greenberg, CEO of FRR and of Fio Corporation.

In early September, FRR announced the first delivery of the COVID-19 workflow software and the Company has since signed additional agreements for trial deployments with other organizations including a subsidiary of a large European diagnostics company which, upon successful completion a feasibility pilot, could result in volume deployments in multiple countries in Africa.

Trial or pilot deployments are designed to enable FRR and clients to customize Fionet for region-based workflows, including safe-return-to-work protocols, community-based COVID-19 testing protocols, and for field stress-testing.

In mid-August Relay Medical and Fio Corp. formed Fionet Rapid Response Group to rapidly adapt the Fionet platform for testing and tracking of COVID-19 to provide a solution that allows for management of mass community-based testing, triage, and contact tracing of the disease. The platform has been successfully deployed in over a dozen countries, where it has performed with excellent results for 1 million tests of high-consequence infectious diseases, including HIV, Ebola, malaria, dengue fever, and others.

Relay Medical and Fio Corporation executed this agreement for COVID based on the anticipation that: (1) for the first wave, all attention would go to personal protective equipment, tests, treatments, and vaccines – which a multitude of other companies would vie to provide; (2) the second wave will be a major threat; (3) by that time, sweeping measures would be needed to protect national and personal economies worn down by the first wave; and, (4) this would drive attention to implementing controlled, mass, community-based testing and triage coupled to real-time data circulation between frontline action and remote decision-making – which FRR can uniquely provide.

“The FRR team is working in unison with client teams to serve a great need and to intercept the opportunity anticipated in the second wave of COVID. Governments and the private sector are moving strongly towards taking the fight against COVID to mass, community-based settings, where people work, live, study, and travel so that they can continue to work, live, study, and travel.” said Yoav Raiter, CEO of Relay Medical Corp.

Fionet has been submitted to Health Canada for expedited access to address community-based testing and tracking. FRR is simultaneously working towards Fionet regulatory approval in the US and EU.

**The Companies are not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

About Fio Corporation

Fio Corporation, privately held and headquartered in Toronto, developed and markets the world’s first integrated guidance & tracking IT platform for decentralized healthcare settings, a new category of solution that raises healthcare quality and lowers healthcare costs. The platform enables average healthcare workers in clinics to deliver a new level of quality-controlled diagnostic testing and case management. Simultaneously, as an automated by-product of its clinical use, the platform captures and provides unprecedented frontline data to remote supervisors and stakeholders, enabling real-time remote tracking, insight distribution, and intervention. Fio operates globally in partnership with local distribution, service, and support organizations and also partners with other companies that license its technologies.

Website: www.fio.com

About Relay Medical Corp.

Relay Medical is a MedTech innovation Company headquartered in Toronto, Canada focused on the development of novel technologies in the diagnostics and AI data science sectors.

Website: www.relaymedical.com

W. Clark Kent
Relay Medical Corp.
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2

Bernhard Langer
EU Investor Relations
Office. +49 (0) 177 774 2314
Email: blanger@relaymedical.com

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the commercialization plans for the Company’s technologies described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com


A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c73e26ec-59f6-4967-825e-53d60a7386d5

Brunswick Announces Closing of Private Placements for Aggregate Proceeds of $3.325 Million

MONTREAL, Oct. 01, 2020 (GLOBE NEWSWIRE) — Brunswick Exploration Inc., formerly Komet Resources Inc. (“Brunwick” or the “Corporation”) is pleased to announce that it has closed its previously announced non-brokered private placements for aggregate gross proceeds of $3.325 million, consisting of the issuance of (i) 12,500,000 units of the Corporation (each, a “Unit“) at a price of $0.13 per Unit, for gross proceeds of $1.625 million and (ii) 10,000,000 flow-through shares of the Corporation (the “FT Shares”), at a price of $0.17 per FT Share, for gross proceeds of $1.7 million (collectively, the “Offerings“).

Each Unit consists of one common share of the Corporation (each, a “Common Share“) and one-half of one common share purchase warrant of the Corporation (each whole warrant, a “Warrant“). Each Warrant entitles the holder thereof to acquire one Common Share at a price of $0.20 for a 24-month period following the closing date of the Offerings.

The net proceeds from the Offerings are expected to be used by the Corporation for the exploration of newly acquired Québec properties ($1.7 million), as well as general corporate purposes ($1.625 million).

In connection to this Offerings, the Corporation paid cash finders fees of $49,323.

The Offerings were carried out pursuant to prospectus exemptions of applicable securities laws and are subject to final acceptance by the TSX Venture Exchange. All securities issuable pursuant to the Offerings are subject to a statutory 4-month hold period from closing in accordance with applicable securities legislation.

As a result of the Offerings, 117,287,368 common shares of the Corporation are issued and outstanding.

About Brunswick

The Corporation is a Montreal-based mineral exploration corporation listed on the TSX-V under symbol KMT. It has put its African assets for sale and is now focused on exploration and development of gold and base metal properties in Eastern Canada. The Corporation’s name change to “Brunswick Exploration Inc.” was approved at the annual meeting of shareholders on September 15, 2020. The Corporation will trade under the symbol TSX-V: BRW effective at market open on October 6, 2020.

Investor Relations/information

Mr. Robert Wares, Chairman and interim President (r.wares@kometgold.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Bombardier Announces Senior Management Reorganization in Support of its Transition to a Pure-play Business Jet Company

MONTRÉAL, Oct. 01, 2020 (GLOBE NEWSWIRE) — Bombardier (TSX: BBD.B) announced today that it has begun the process of streamlining its senior leadership team as it transitions to a pure-play business jet company.  As part of this process, the Company has eliminated the Bombardier Aviation president role and announced that David Coleal will depart the Company.

“With the sale of Bombardier Transportation nearing completion, we are preparing for our future as a business aviation company,” said Éric Martel, President and Chief Executive Officer, Bombardier Inc. “Our goal is to create a leaner, more agile and customer-centric company to better capture growth opportunities with our industry leading business jet portfolio. This includes simplifying our corporate leadership structure.”

“I want to acknowledge and thank David Coleal for his many contributions to Bombardier,” Martel continued. “We wish David continued success in his future endeavours.”

About Bombardier
With nearly 60,000 employees across two business segments, Bombardier is a global leader in the transportation industry, creating innovative and game-changing planes and trains. Our products and services provide world-class transportation experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.

Headquartered in Montréal, Canada, Bombardier has production and engineering sites in over 25 countries across the segments of Aviation and Transportation. Bombardier shares are traded on the Toronto Stock Exchange (BBD). In the fiscal year ended December 31, 2019, Bombardier posted revenues of $15.8 billion. News and information are available at bombardier.com or follow us on Twitter @Bombardier.

Bombardier is a trademark of Bombardier Inc. and its subsidiaries.

For Information
Jessica McDonald
Media Relations and Public Affairs
Bombardier Inc.
+1 514 262 7255

Informa Pharma Intelligence Launches New Pulse Report: Clinical Trials & the COVID-19 Vaccine

Findings Uncover More than 1 in 3 Americans Don’t Trust How Quickly COVID-19 Vaccine Clinical Trials Are Moving

LONDON, Oct. 01, 2020 (GLOBE NEWSWIRE) — Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, today released its “Pulse Report: Clinical Trials & the COVID-19 Vaccine” study which uncovered American sentiment and confidence around COVID-19 vaccine clinical trials. According to the data, more than 1 in 3 (35%) Americans don’t trust how quickly the COVID-19 vaccine clinical trials are moving, and more than 1 in 5 (23%) don’t think pharmaceutical companies have consumers’ best interests at mind during COVID-19 vaccine clinical trials.

The study conducted with third-party research firm YouGov, found that while Americans are wary of the current vaccine development process, they are paying attention to it with 22% saying they regularly look for updates on COVID-19 vaccine clinical trials. As such, developers must prioritize further education and transparency around the process. Right now, 1 in 5 Americans agree that both pharmaceutical companies and the government are NOT communicating enough about COVID-19 vaccine clinical trials (20% and 21% respectively).

To quell these growing concerns and get Americans on board with a vaccine, data highlighted that developers should look to fill information gaps. Many Americans say they’re more likely to take the COVID-19 vaccine if they:

  • Had more information on clinical trials: more than 1 in 4 (28%)
  • Knew the demographic breakdowns of clinical trials were diverse: almost 1 in 6 (15%)
  • Could directly ask questions about clinical trials to vaccine developers: more than 1 in 10 (12%)
  • Knew someone who had participated in a clinical trial: more than 1 in 10 (11%)

“There’s a clear demand for unbiased information from the American public when it comes to COVID-19 vaccine clinical trials,” said Duncan Emerton, PhD, Director, Custom Intelligence & Analytics, Pharma Intelligence. “As we try to make it through this global pandemic together, there is a critical need for transparency from those racing to develop a COVID-19 vaccine. With a large portion of Americans already voicing their apprehension around taking a vaccine upon approval, education will be a key component in changing their attitude. A vaccine can only work if people are willing to be vaccinated. If the public doesn’t trust it, all of the industry’s efforts will have been for nothing.”

As the vaccine approval race heats up, developers leading the pack should be at the forefront of this knowledge sharing push. Data found that 57% of Americans have heard of at least one COVID-19 vaccine developer within Phase 3 clinical trials but some are more recognized than others. Among those with a COVID-19 vaccine in Phase 3 clinical trials:

  • 38% of Americans have heard of AstraZeneca & University of Oxford
  • 25% of Americans have heard of Moderna & National Institute of Health
  • 20% of Americans have heard of BioNTech & Pfizer & Fosun Pharma
  • 18% of Americans have heard of Wuhan Institute of Biological Products

The full report will be available at www.pharmaintelligence.informa.com.

Research Methodology
Informa Pharma Intelligence commissioned YouGov PLC – a third party, professional research and consulting organization – to poll the views of 1,346 adults who agreed to take part. Fieldwork was undertaken between 3rd – 4th September 2020. The survey was carried out online. The figures have been weighted and are representative of all US adults (aged 18+).

About Informa Pharma Intelligence
Informa Pharma Intelligence powers a full suite of analysis products—Datamonitor Healthcare™, Sitetrove™, Trialtrove™, Pharmaprojects™, Medtrack™, Biomedtracker™, Scrip™, Pink Sheet™ and In Vivo™ – to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.

With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com.

Media Contacts:
Diffusion PR for Informa Pharma Intelligence